Home > Neurology > ECTRIMS 2021 > Treatment Trials and Strategies > ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

Presented By
Prof. Xavier Montalban, Vall d’Hebron University Hospital, Spain
At a joint session on behalf of ECTRIMS and the European Academy of Neurology (EAN), an update was presented of the ECTRIMS/EAN Clinical Guidelines on the treatment of people with MS. At the time of the presentation, this document had not yet been published [1]. Prof. Xavier Montalban (Vall d’Hebron University Hospital, Spain) summarised the 2021 update of the ECTRIMS/EAN guidelines. The update is divided into 8 topics, of which the first is efficacy of disease-modifying therapy (DMT). The following recommendations were included: Offer interferon or glatiramer acetate to patients with clinically isolated syndrome (CIS) highly suggestive of MS and an abnormal MRI with lesions suggestive of MS who do not fulfil criteria for MS. Offer treatment with siponimod to patients with secondary progressive MS (SPMS) with evidence of inflammatory activity (relapses and/or MRI activity). Treatment with other DMTs u...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on